Six-Month HIV Prevention Shot Achieves 99% Efficacy in Major Study
Lenacapavir, a new twice-yearly injection, offers 96% HIV prevention efficacy, surpassing daily oral PrEP. For oral ...
A twice-yearly shot could help end AIDS. But will it get to everyone who needs it?
Drugmaker Gilead said it will allow cheap, generic versions to be sold in 120 poor countries with high HIV rates, mostly in ...
We can end AIDS - but will we seize the opportunity?
We still have 1.3 million new infections a year, the majority of which occur in marginalised and vulnerable groups. But we ...
HIV prophylactic lenacapavir — very safe and very expensive
Health experts say lenacapavir could reduce the number of global HIV infections significantly. But it needs to be cheaper to be effective.When lenacapavir test results were presented at a World AIDS ...
HIV Breakthrough as New Injection 89% More Effective Than PrEP
"PrEP reduces the risk of getting HIV from sex by about 99 percent when taken as prescribed. Although there is less ...
clinicaltrialsarena3d
Gilead’s twice-yearly lenacapavir shows promise in HIV prevention trial
Gilead Sciences has announced the outcomes from the Phase III PURPOSE 2 trial evaluating lenacapavir for HIV prevention.
Gilead's Twice-Yearly Lenacapavir Reduces HIV Infection Risk
According to a study published in the New England Journal of Medicine, twice-yearly injection of Lenacapavir offers a 96 percent ...
'Huge relief' as new drug found to effectively prevent HIV infection
A vaccination with the drug lenacapavir offers an effective protection against a HIV infection, according to newly published ...
BMJ3d
Gilead’s anti-diversion clause for lenacapavir exploits vulnerable communities
Following the promising multicentre, international Purpose 1 and Purpose 2 clinical trials with lenacapavir for HIV ...